Stephen F. Betz Crinetics Pharmaceuticals, Inc. (CRNX) insider trading activity

Stephen F. Betz is Chief Scientific Officer of Crinetics Pharmaceuticals, Inc.. Currently has a direct ownership of 68,576 shares of CRNX, which is worth approximately $3.94 Million. The most recent transaction as insider was on Nov 01, 2022, when has been sold 3,126 shares (Common Stock) at a price of $18.52 per share, resulting in proceeds of $57,893. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 68.6K

1.49% 3M change

19.6% 12M change

Total Value Held $3.94 Million

Stephen F. Betz Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 01 2022	SELL Open market or private sale	$57,893 $18.52 p/Share	3,126 Reduced 3.31%	91,220 Common Stock
Oct 17 2022	SELL Open market or private sale	$55,424 $17.73 p/Share	3,126 Reduced 3.21%	94,346 Common Stock
Oct 03 2022	SELL Open market or private sale	$61,395 $19.64 p/Share	3,126 Reduced 3.11%	97,472 Common Stock
Sep 15 2022	SELL Open market or private sale	$87,570 $21.01 p/Share	4,168 Reduced 3.98%	100,598 Common Stock
Sep 07 2022	SELL Open market or private sale	$21,882 $21.0 p/Share	1,042 Reduced 0.98%	104,766 Common Stock
Sep 01 2022	SELL Open market or private sale	$58,112 $18.59 p/Share	3,126 Reduced 2.87%	105,808 Common Stock
May 20 2022	BUY Other acquisition or disposition	$14,723 $11.02 p/Share	1,336 Added 1.21%	108,934 Common Stock
May 02 2022	SELL Open market or private sale	$65,265 $20.1 p/Share	3,247 Reduced 2.93%	107,598 Common Stock
Apr 18 2022	SELL Open market or private sale	$146,188 $25.81 p/Share	5,664 Reduced 4.86%	110,845 Common Stock
Apr 04 2022	SELL Open market or private sale	$215,730 $23.97 p/Share	9,000 Reduced 7.17%	116,509 Common Stock
Apr 01 2022	SELL Open market or private sale	$90,775 $21.8 p/Share	4,164 Reduced 3.21%	125,509 Common Stock
Mar 31 2022	SELL Open market or private sale	$87,694 $21.06 p/Share	4,164 Reduced 3.11%	129,673 Common Stock
Mar 15 2022	SELL Open market or private sale	$59,150 $18.94 p/Share	3,123 Reduced 2.28%	133,837 Common Stock
Mar 01 2022	SELL Open market or private sale	$61,617 $19.73 p/Share	3,123 Reduced 2.23%	136,960 Common Stock
Feb 28 2022	BUY Grant, award, or other acquisition	-	16,500 Added 10.54%	140,083 Common Stock
Feb 15 2022	SELL Open market or private sale	$58,213 $18.64 p/Share	3,123 Reduced 2.46%	123,583 Common Stock
Feb 01 2022	SELL Open market or private sale	$58,681 $18.79 p/Share	3,123 Reduced 2.41%	126,706 Common Stock
Jan 18 2022	SELL Open market or private sale	$97,073 $23.29 p/Share	4,168 Reduced 3.13%	128,875 Common Stock
Jan 03 2022	SELL Open market or private sale	$200,847 $28.02 p/Share	7,168 Reduced 5.11%	133,043 Common Stock
Dec 28 2021	SELL Open market or private sale	$83,850 $27.95 p/Share	3,000 Reduced 2.09%	140,211 Common Stock
Dec 15 2021	SELL Open market or private sale	$136,826 $24.14 p/Share	5,668 Reduced 3.81%	143,211 Common Stock
Dec 01 2021	SELL Open market or private sale	$155,190 $27.38 p/Share	5,668 Reduced 3.67%	148,879 Common Stock
Nov 16 2021	SELL Open market or private sale	$41,955 $27.97 p/Share	1,500 Reduced 0.96%	154,547 Common Stock
Nov 15 2021	SELL Open market or private sale	$151,619 $26.75 p/Share	5,668 Reduced 3.5%	156,047 Common Stock
Nov 08 2021	SELL Open market or private sale	$110,838 $28.42 p/Share	3,900 Reduced 2.35%	161,715 Common Stock

SFB

Stephen F. Betz

Chief Scientific Officer

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CRNX shares.

Notify only if

Value

Insider Trading

Get notified when an Crinetics Pharmaceuticals, Inc. insider buys or sells CRNX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Crinetics Pharmaceuticals, Inc.

Track Activities on CRNX

Account